116 related articles for article (PubMed ID: 8868016)
21. Blood glucose concentrations and glycosuria during and after one year of acarbose therapy.
Aubell R; Boehme K; Berchtold P
Arzneimittelforschung; 1983; 33(9):1314-8. PubMed ID: 6357206
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of acarbose in type 2 diabetes mellitus in Jamaica.
Morrison EY; Wright-Pascoe R; Aquart A; Robinson H; Banbury M; Whitbourne F; Callender J; Less L; Bailey S
West Indian Med J; 2000 Dec; 49(4):285-9. PubMed ID: 11211536
[TBL] [Abstract][Full Text] [Related]
23. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
Rosak C; Haupt E; Walter T; Werner J
Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
[TBL] [Abstract][Full Text] [Related]
24. [Inhibition of intestinal alpha glucosidases in the therapy of diabetes mellitus].
Fölsch UR; Lembcke B
Internist (Berl); 1991 Dec; 32(12):699-707. PubMed ID: 1823561
[No Abstract] [Full Text] [Related]
25. Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.
Singh KP; Periyandavar I; Rajadhyaksha GC; Jayaram S; Mishra AB; Kinagi S; Sharma A; Baliga VP
J Indian Med Assoc; 2007 Jun; 105(6):344, 346, 350. PubMed ID: 18232183
[TBL] [Abstract][Full Text] [Related]
26. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
[TBL] [Abstract][Full Text] [Related]
27. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
Rosak C; Hofmann U; Paulwitz O
Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
[TBL] [Abstract][Full Text] [Related]
28. [New, in Austria registered specialty drugs. Glucobay (acarbose)].
Sturm M
Wien Klin Wochenschr; 1992; 104(11):329-36. PubMed ID: 1621396
[No Abstract] [Full Text] [Related]
29. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
Hermanns N; Burkert A; Haak T
Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):310-4. PubMed ID: 15216448
[TBL] [Abstract][Full Text] [Related]
30. [Short term assessment of anthropometric indices and metabolic parameters in obese subjects treated with acarbose].
Coli P; Pea E; Lacorte M; Passaglia C; Carrai M
Minerva Med; 1996 Apr; 87(4):161-70. PubMed ID: 8700340
[TBL] [Abstract][Full Text] [Related]
31. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.
Santeusanio F; Compagnucci P
Drug Saf; 1994 Dec; 11(6):432-44. PubMed ID: 7727053
[TBL] [Abstract][Full Text] [Related]
32. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes.
Ogawa S; Takeuchi K; Ito S
Diabetes Obes Metab; 2004 Sep; 6(5):384-90. PubMed ID: 15287932
[TBL] [Abstract][Full Text] [Related]
33. Beneficial effects of acarbose on daily plasma glucose profile and cataract development in sand rats.
Madar Z; Hazan A; Pollack A
Eye (Lond); 1994; 8 ( Pt 3)():353-6. PubMed ID: 7958047
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K
Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Hoffmann J; Spengler M
Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
Bressler R; Johnson DG
Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
[TBL] [Abstract][Full Text] [Related]
37. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
[TBL] [Abstract][Full Text] [Related]
38. [Acarbose--a new therapeutic principle in diabetes mellitus therapy].
Schöffling K; Hillebrand I
Dtsch Med Wochenschr; 1981 Aug; 106(35):1083-4. PubMed ID: 6114844
[No Abstract] [Full Text] [Related]
39. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus.
Balfour JA; McTavish D
Drugs; 1993 Dec; 46(6):1025-54. PubMed ID: 7510610
[TBL] [Abstract][Full Text] [Related]
40. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB; Bray GA
Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
